"We are pleased with the approval to start our Phase I program with TG-C and feel that our drug candidate has the potential to be not first-in-class, but also best-in-class," stated Dr. K.H. Lee, President, founder and Chief Executive Officer of TissueGene.
TG-C has been developed by TissueGene to regenerate cartilage in patients suffering from degenerative arthritis and more specifically for indications such as osteoarthritis of the knee.
TG-C involves minimal invasive injections versus a surgical approach and poses as an alternative to other methods of cartilage repair as opposed to current available techniques that involve multiple and often invasive surgical procedures but still has mixed results.
Read more at PR Newswire.
.jpg)
Comment Preview